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Abstract
Bypassing tyrosine kinases responsible for Stat5a/b phosphor-
ylation would be advantageous for therapy development for
Stat5a/b-regulated cancers. Here, we sought to identify small
molecule inhibitors of Stat5a/b for lead optimization and therapy
development for prostate cancer and Bcr-Abl–driven leukemias.
In silico screening of chemical structure databases combined with
medicinal chemistrywas used for identificationof a panel of small
molecule inhibitors to block SH2 domain–mediated docking of
Stat5a/b to the receptor-kinase complex and subsequent phos-
phorylation and dimerization. We tested the efficacy of the lead
compound IST5-002 in experimental models and patient
samples of two known Stat5a/b-driven cancers, prostate cancer
and chronic myeloid leukemia (CML). The lead compound
inhibitor of Stat5-002 (IST5-002) prevented both Jak2 and
Bcr-Abl–mediated phosphorylation and dimerization of Stat5a/
b, and selectively inhibited transcriptional activity of Stat5a
(IC50 ¼ 1.5mmol/L) and Stat5b (IC50 ¼ 3.5 mmol/L). IST5-002
suppressed nuclear translocation of Stat5a/b, binding toDNAand
Stat5a/b target gene expression. IST5-002 induced extensive apo-
ptosis of prostate cancer cells, impaired growth of prostate cancer
xenograft tumors, and induced cell death in patient-derived
prostate cancers when tested ex vivo in explant organ cultures.
Importantly, IST5-002 induced robust apoptotic deathnot only of
imatinib-sensitive but also of imatinib-resistant CML cell lines
and primary CML cells from patients. IST5-002 provides a lead
structure for further chemical modifications for clinical develop-
ment for Stat5a/b-driven solid tumors and hematologic malig-
nancies. Mol Cancer Ther; 14(8); 1777–93. 2015 AACR.
Introduction
There is an unmet medical need for pharmacologic inhibitors
of signal transducer and activator of transcription 5a/b (Stat5a/b).
Stat5a/b is critical for growth and progression of solid tumors
and hematologic malignancies, specifically prostate cancer (1–9)
and Bcr-Abl–driven leukemias (10–19), respectively. In prostate
cancer, effective therapeutic options are lacking for advanced
castrate-resistant prostate cancer (CRPC), for which Stat5a/b is
an experimentally established therapeutic target candidate
(2, 4, 9, 20, 21). Multiple findings support Stat5a/b as a thera-
peutic target protein in prostate cancer: (i) inhibition of Stat5a/b
expression or activation induces rapid apoptotic prostate cancer
cell death (1–3, 9, 22); (ii) blockade of Stat5a/b signaling inhibits
growth of both primary prostate cancer and CRPC (2, 4, 5, 9, 21–
23); (iii) Stat5a/b promotes epithelial–mesenchymal transition
(EMT) and metastasis of human prostate cancer (5); (iv) the
Stat5a/b gene locus is frequently amplified in clinical prostate
cancers during progression to metastatic CRPC (6); (v) Stat5a/b
activation in prostate cancer predicts early recurrence and prostate
cancer–specific death (7, 8, 21).
Chronic myeloid leukemia (CML) is a clonal hematopoietic
stem cell malignancy characterized by the unique t(9:22) (q34:
q11) translocation, which generates the BCR-ABL oncogene (24).
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Bcr-Abl is a constitutively active tyrosine kinase promoting trans-
formation, proliferation, and survival of CML cells via Stat5a/b
signaling (10–19, 25). Resistance to the predominant pharma-
cologic inhibitor of Bcr-Abl, imatinib mesylate (Gleevec; ref. 26),
induced by point mutations within the Abl kinase domain or
overexpression of Bcr-Abl (27, 28), is, in part, dependent on
activation of the Stat5a/b signaling pathway (10, 14, 18).
Stat5a/b includes two highly homologous isoforms Stat5a and
Stat5b (hereafter referred to as Stat5a/b), which display >90%
amino acid identity and are encoded by genes juxtaposed on
chromosome 17q21.2 (29). Stat5a/b are latent cytoplasmic pro-
teins that function as both signaling proteins and nuclear tran-
scription factors. Activation of Stat5a/b occurs through inducible
phosphorylation of a conserved C-terminal tyrosine residue (29).
Phosphorylated Stat5a/b (pY694/699) molecules form function-
al parallel dimers that translocate to the nucleus and bind specific
DNA response elements (29). Stat5a/b proteins comprise five
functional domains: (i) N-terminal domain (29); (ii) coiled-coil
domain (30); (iii) DNA-binding domain (29); (iv) Src-homology
2 (SH2) domain, which mediates receptor-specific recruitment
and Stat5a/b dimerization (29); and (v) C-terminal transactiva-
tion domain (29). In prostate cancer, Stat5a/b is activated by the
upstreamkinase Jak2 andbyother tyrosine kinases such as Src and
growth factor receptors (31–34). In CML, Stat5a/b is phosphor-
ylated directly by Bcr-Abl (35) and targeting Stat5a/b would
bypass Bcr-Abl and might provide an effective therapy especially
in imatinib-resistant CML (10–19, 25). Therefore, targeting of
Stat5a/b as a cytoplasmic signaling protein in both prostate cancer
and CML may prove a more effective therapeutic strategy than
inhibiting Stat5a/b tyrosine kinases.
In this study, we identified a small molecule inhibitor family of
Stat5a/b through structure-based in silico screening andmedicinal
chemistry by targeting the Stat5a/b SH2domain. The SH2domain
of a Stat5 monomer docks transiently to a phospho-tyrosyl
moiety of a tyrosine kinase complex, which facilitates phosphor-
ylation of Y694/699 residue of Stat5a/b. The SH2 domain of each
phosphorylated Stat5 monomer forms transcriptionally active
parallel dimers through binding of pY694/699 residue of the
partner Stat5 monomer (36). Therefore, a small molecule that
interferes with the SH2 domain should inhibit both Stat5a/b
phosphorylation and dimerization. Our lead compound, inhib-
itor of Stat5-002 (IST5-002) blocked both Jak2 and Bcr-Abl–
mediated phosphorylation of Stat5a/b and disrupted dimeriza-
tion, nuclear translocation, DNA binding, and transcriptional
activity. IST5-002 induced apoptotic death of prostate cancer cells
and imatinib-sensitive and -resistant CML cells in vitro. Further-
more, IST5-002 inhibited growth of prostate cancer xenograft
tumors in vivo and Stat5a/b-positive patient-derived prostate
cancers in ex vivo organ culture. These findings establish a potent
small molecule Stat5a/b inhibitor compound for further optimi-
zation and therapy development for prostate cancer and Bcr-Abl–
driven leukemias.
Materials and Methods
Discovery of small molecule Stat5 inhibitor IST5-002 through
in silico database screen
To identify candidate compounds that disrupt Stat5a/b dimer-
ization by targeting the SH2 domain, we created a three-dimen-
sional model of the SH2 domain dimer structure (amino acid
residues 589-710) of human Stat5b using the homology model-
ing software, MODELLER 6v2. The sequence of the human Stat5b
SH2 domain with an additional 14 amino acids (697-DGYVKP-
QIKQVVPE-710) at the C-terminus, containing the phosphotyr-
osine (UniProtKB/Swiss-Prot ID:P51692), was used to search for
sequences that matched the sequences of three-dimensional
structures of proteins and their complexes available in the Protein
Data Bank using BLAST (National Center for Biological Informa-
tion). The sequence homology between human STAT5A and
STAT5B is approximately 92%, whereas the sequence homology
between the SH2 domains of human STAT5A and STAT5B is
approximately 98% (29).We identified two protein structures: (i)
Stat3–DNA complex (PDB ID: 1BG1; ref. 30), with identities
equal to 35%, positives equal to 11%, and gaps equal to 53%);
and (ii) tyrosine-phosphorylated Stat1–DNA complex (PDB ID:
1BF5; ref. 37), with identities equal to 56%, positives equal to
34%, and gaps equal to 12%) with expected values (e-value) of
9e14 and 7e12, respectively. By aligning the sequences
between the SH2 domains of human STAT5B and STAT3 and
using the crystal structure of the SH2 domain of the Stat3–DNA
complex as a template, a homology model of the SH2 domain of
human Stat5b was built. This homology model was further
energy-minimized until the root-mean-square deviation was <
0.09 using AMBER7 (UCSF) and its force field with a distance-
dependent dielectric constant. To perform structure-based in silico
screening, the pY binding subpocket is insufficient to identify
Figure 1.
Identification and functional characterization of the Stat5a/b inhibitor IST5-002. A, ribbon presentation of the crystal structure of Stat–DNA complex and
the various functional domains are labeled. Predicted binding model of IST5-002 to the Stat5a SH2 domain, shown as atom-based (carbon, white; oxygen,
red; nitrogen, blue; phosphorous, cyan; sulfur, yellow) bonds within the binding site at the SH2 dimer interface (B), and by stick model, depicting the
SH2 dimer interface site of Stat5a (magenta) with labeled subpockets P1, P2, P3, and P1' of the SH2 interface (C). D, chemical structures of the Stat5a/b
inhibitor IST5-002 and the control compound (Ctrl) with similar molecular weight as IST5-002. E, IST5-002 inhibits transcriptional activity of Stat5a/b. PC-3
cells were transiently cotransfected with a b-casein-promoter-luciferase plasmid, pRL-TK (Renilla luciferase), pPrl-receptor (PrlR), pStat5a or pStat5b,
as indicated. Cells were serum starved (0% FBS; 10 hours) and pretreated with IST5-002 or Ctrl at the indicated concentrations (2 hours), followed by
stimulation with 10 nmol/L human prolactin (hPrl; 16 hours). Relative luciferase activities were determined, and mean values of three independent
experiments performed in triplicate  SE values are indicated by bars. F and G, IST5-002 inhibits Bcr-Abl–driven (F) and Jak2-driven (G) Stat5
phosphorylation. Whole-cell lysates of exponentially growing K562 cells and Stat5a/b immunoprecipitates of CWR22Rv1 cells were immunoblotted with anti-
pYStat5 mAb, anti-Stat5a/b mAb, anti-pY mAb (for Jak2), anti-c-Abl pAb, or anti-actin pAb as loading control. In CWR22Rv1 cells, Stat5 and Jak2 were
immunoprecipitated using anti-Stat5a or anti-Jak2 pAbs from serum-starved CWR22Rv1 cells (16 hours), treated with IST5-002 (2 hours), followed by
stimulation with 10 nmol/L hPrl (30 minutes). H, IST5-002 suppresses Stat5 dimerization. pCMV-3Flag-Stat5a, pCMV-3Mys-Stat5a, and pPrlR plasmids were
cotransfected into PC-3 cells. Cells were serum-starved (16 hours), pretreated with IST5-002 or Ctrl at indicated concentrations (2 hours), followed by
stimulation with 10 nmol/L hPrl (30 minutes). 3-Myc-Stat5a was immunoprecipitated with anti-Myc mAb and blotted with anti-Flag mAb or anti-Myc mAb, as
indicated. Whole-cell lysates were blotted with anti-Myc, anti-Flag mAb, or anti-actin pAb to demonstrate the input.
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potent inhibitors against the dimer of SH2 domains, requiring
additional two to three subpockets near the pY binding pocket.
Fromanalysis of the crystal structure of the Stat1–DNAcomplex at
the SH2 dimer interface, it is clear that additional subpockets are
available both at theN- andC-termini of the pY-binding site at the
dimer interface. In order to identify these additional subpockets,
64 oligopeptides derived from the tetrapeptide sequence pYVKP
(where pY is the phosphorylated tyrosine) by varying the amino
acids to all eight hydrophobic/aromatic acids independently
both at the second and fourth amino acid positions and docked
into the binding site on the SH2 domain. By calculating the
interaction energies of all 64 amino acids and rank-ordering them,
we selected the following residues of Stat5b as the binding sites
for in silico screening: 600K, 604H, 618-RFSDSEIGG-626, 628T,
638-RMFWNLMPF-646, 707-VVPE-710.
In silico screening of small organic molecules from databases
(NCI, Maybridge, LeadQuest, Virtual Chemistry, and Drug-Like
Compounds; http://www.chemnavigator.com) of 30 million
compounds was performed against the subpockets at the
dimer interface for their ability to disrupt Stat5b dimerization
(Fig. 1A–C).Wewanted to identify compounds thatwouldmimic
the side chain of pY and have additional groups occupying the
subpockets described above. In our first-level search, we identified
compounds with free phosphate group attached either to an
aromatic or aliphatic five- or six-member ring. These compounds
were screened against the phosphotyrosine-binding pocket using
aflexible ligand docking program (FlexXmodule of Sybyl, Tripos)
and multiple scoring functions (molecular mechanics energy,
surface area, etc.), which led to the selection of the top-ranking
100 compounds. These compounds, along with their protein
complexes, were energy-minimized using molecular mechanics
CFF91 force-filed to better fit the ligands into the binding pocket.
The top-ranking 30 small molecule inhibitors were selected from
visual analysis of docking position and interactions to be further
validated in biologic assays, and as the basis of the design and
synthesis of compound analogs (Supplementary Fig. S1).
Cell lines and reagents
PC-3, DU145, and LNCaP prostate cancer cells, T47D breast
cancer cells, and CML-cells (KCL22, K562, and BV173; all from
ATCC in 2002), were cultured in RPMI-1640 (Mediatech) con-
taining penicillin (50 IU/mL)/streptomycin (50 mg/ml; Media-
tech), and 10% fetal bovine serum (FBS; Gemini BioProducts).
CWR22Rv1 cells were provided by Dr. Thomas Pretlow (Case-
western Reserve University, Cleveland, OH) in 2004. K562, ima-
tinib-resistant K562 (K562R), BV173, imatinib-resistant-BV173
(BV173T315I) were maintained in Iscove's Modified Dulbecco's
Medium (IMDM; Mediatech) supplemented with 1% penicillin/
streptomycin, L-glutamine, and 10% FBS. KCL22R, K562R, and
BV173R were kindly provided by Dr. Nicholas J. Donato (2009;
University of Michigan, Ann Arbor, MI). SUP-B15, 12878, and
3798 (2009; Coriell Institute, Camden, NJ) were maintained
in Iscove's medium with 10% FBS. LNCaP cells were supplemen-
ted with 0.5 nmol/L dihydrotestosterone (DHT; Sigma-Aldrich).
CML CD34þ cells from three CML patients (#3-342, #9537, and
#3-295; 2010, a gift from Dr. Tessa Holyoake, University of
Glasgow, Scotland, United Kingdom) were maintained in
serum-free expansion medium (SFEM; STEMCELL Technologies)
supplemented with 1% penicillin/streptomycin and L-glutamine
(Gibco), a cytokine cocktail (100 ng/mL Flt3 ligand, 100 ng/mL
SCF, 20 ng/mL interleukin (IL)-3, and 20 ng/mL IL6 (STEMCELL
Technologies), and 100 ng/mL rhTPO (Prospec). Monkey kidney
fibroblast (COS-7), human lung cancer (A549), fibrosarcoma
(HT1080), pancreatic cancer (CAPAN), and liver cancer (HepG2)
cell lines (all from ATCC in 2008) were grown in DMEM (Invi-
trogen) supplemented with 10% FBS, 2mmol/L L-glutamine, and
penicillin–streptomycin (Mediatech). All cell lines included in
this study have been authenticated on a regular basis in the users'
laboratory. The testing has been conducted by DNA fingerprint-
ing, isozyme collection, observation of characteristic cell mor-
phology, hormone/growth factor responsiveness, and the expres-
sion of cell lines specific markers such as prostate-specific antigen
(PSA), hormone receptors, Stat3/Stat5, Erk1/2Protein, BCR-Abl.
All cell lines were tested for Mycoplasma contamination (PCR
Mycoplasma Detection Set; Takara Bio Inc.,) every 3 months.
Pimozide was obtained from Sigma-Aldrich.
Luciferase reporter gene assays
PC-3 cells (2  105) were transiently cotransfected with
0.25 mg of pStat5a or pStat5b and pPrlR (prolactin receptor;
PrlR), 0.5 mg of p-b-casein-luciferase (b-casein-Luc) and
0.025 mg of pRL-TK (Renilla luciferase). After 24 hours, cells
were serum-starved for 10 hours, pretreated with compounds
at indicated concentrations for 1 hour, and stimulated with
10 nmol/L human prolactin (hPrl) for 16 hours. For determi-
nation of Stat3 transcriptional activity, 0.25 mg of pcDNA-
Stat3, 0.25 mg of pcDNA-IL6-R, 0.5 mg of pStat3-luciferase
(Panomics), and 0.025 mg of pSV-b-Gal (Promega) were
cotransfected to LNCaP cells, followed by serum-starvation
and stimulation with 50 ng/mL IL6 (Prospec) for 16 hours.
Cell lysates were assayed for firefly and Renilla luciferase activ-
ities using the Dual-Luciferase Reporter Assay System (Pro-
mega), as described previously (23).
Protein solubilization, immunoprecipitation, and
immunoblotting
Cell pellets were immunoprecipitated and immunoblotted as
described previously (2, 3, 5, 23). Stat5a, Stat5b, and Jak2 were
immunoprecipitated fromwhole-cell lysateswith anti-Stat5a, anti-
Stat5b (4 mL/mL; Millipore), or anti-Jak2 (Millipore) pAbs. For
immunoblotting, primary antibodies were used at the following
concentrations: anti-phosphotyrosine-Stat5a/b (Y694/Y699)mAb
Table 1. Prostate cancers cultured ex vivo in explant organ cultures
Age at the
day of operation
Gleason
grade
Gleason
score Stage
Nuclear Stat5
levels
58 (3þ4) 7 T3a 3
66 (4þ3) 7 T2b 3
72 (4þ3) 7 T1c 3
55 (3þ4) 7 T2b 3
66 (3þ4) 7 T1c 2
60 (3þ4) 7 T2a 2
55 (3þ4) 7 T2a 3
67 (3þ4) 7 T2a 2
50a (3þ4) 7 T2b 1
65a (4þ3) 7 T2c 1
66a (4þ3) 7 T3a 0
NOTE: Ages of the patients ranged from 50 to 72 years at the time of the
operation (mean age 62 years).
aProstate cancer samples that did not respond to IST5-002 by cancer cell death.
Samples of each prostate cancer were scored for nuclear Stat5 levels on a scale
from 0 to 3 where 0 represented negative, 1 weak, 2 moderate, and 3 strong
immunostaining.
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Figure 2.
IST5-002 inhibits Stat5 nuclear
translocation andDNAbinding of Stat5
target genes. A, IST5-002 inhibits Prl-
induced nuclear translocation of Stat5
in prostate cancer cells. PC-3 cellswere
infected with adenoviruses expressing
wild-type Stat5a (AdWTStat5a; MOI¼
4) and human Prl-receptor (AdPrlR;
MOI ¼ 4). Serum-starved (16 hours)
cellswere treatedwith IST5-002orCtrl
(2 hours), followed by stimulation with
10 nmol/L hPrl (30 minutes).
Immunostaining of Stat5 is
demonstrated by indirect
immunofluoresence (green), while
DAPI staining (blue) shows the nuclei.
B, IST5-002 inhibits binding of Stat5 to
DNA shown by EMSA analysis using
the Stat5-response element of
b-casein gene as the probe. COS-7
cells were transiently cotransfected
with pStat5a and pPrlR, serum
starved (10 hours), and treated with
IST5-002 or Ctrl at indicated
concentrations (2 hours) followed by
stimulation with 10 nmol/L hPrl (30
minutes). The specificity of the
Stat5–DNA binding complex was
demonstrated by supershift with anti-
Stat5a pAb versus normal rabbit serum
(NRS). C, IST5-002 does not inhibit
nuclear translocation of Stat3 in
prostate cancer cells. Serum-starved
DU145 cells were pretreated with IST5-
002, AZD1480, or vehicle
(2 hours) before stimulation with
5 nmol/L IL6 (30 minutes).
Immunostaining of Stat3 is
demonstrated by indirect
immunofluoresence (green), while
DAPI staining (blue) shows the nuclei.
D, IST5-002 does not inhibit
transcriptional activity of Stat3 in
prostate cancer cells. LNCaP cells were
transiently cotransfected with pStat3,
pIL6-receptor (pIL6R), pStat3-Luc,
and pRL-TK (Renilla luciferase). Cells
were serum-starved (10 hours),
pretreated with 6.0 mmol/L IST5-002,
or Ctrl (2 hours), followed by
stimulation with 50 ng/mL IL6 (16
hours). Relative luciferase activities
were determined, and mean values of
three independent experiments
performed in triplicate SE values are
indicated by bars.
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(1 mg/mL; Advantex BioReagents), anti-Stat5ab mAb (1:250; BD
Biosciences), anti-c-Abl mAb (1:500; Calbiochem), anti-Grb2
mAb (5:100; BD Biosciences), anti-b-actin pAb (1:4,000; Sigma),
anti-cyclin D1 mAb (1:1,000; BD Biosciences), anti-pPAK1/2
(1:1,000; Cell Signaling Technology), anti-Bcl-xL pAb (1:1,000;
Cell Signaling Technology), and anti-phosphotyrosine mAb
(1:1,000; Millipore).
Cell-based immunoassay for tyrosine-phosphorylated Stat5a/b
T47D cells in 96-well plates were serum-starved for 16 hours,
pretreatedwith IST-002 at the indicated concentrations for 2 hours,
followed by stimulation with hPrl (2 nmol/L) for 15minutes, and
fixation in 20C acetone/methanol followed by incubation with
anti-pStat5a/b rabbit mAb (1:200; Cell Signaling Technology) and
secondary horseradish peroxidase (HRP)–conjugated anti-rabbit
Ab (1:2,000; Cell Signaling Technology). The amount of phospho-
Stat5a/b was evaluated using 1-Step Ultra TMB substrate (Thermo
Scientific) at 450 nm. Cells cultured in the absence of IST-002 and
treated with or without prolactin served as positive and negative
controls, respectively. The inhibition curve and IC50 were derived
from triplicate measurements using SigmaPlot.
Kinase activity assay
Inhibitory activity of IST5-002 was tested against a panel of 50
kinases using KinaseSeeker Technology (Luceome Biotechnolo-
gies). Prior to initiating the kinase profiling, IST5-002 was eval-
uated for false positive activity against split-luciferase. For the
kinase assays, each Cfluc-Kinase was translated along with Fos-
Nfluc using a cell-free system (rabbit reticulocyte lysate) at 30C
for 90minutes. An aliquot (24 mL) of this lysate containing either
1 mL of DMSO (for no-inhibitor control) or compound solution
in DMSO (1 mmol/L final concentration) was incubated for 30
minutes at room temperature followed by 1 hour in the presence
of a kinase-specific probe. Eighty microliters of luciferin assay
reagent was added to each solution and luminescence was imme-
diately measure in a luminometer. Profiling data for all kinases
were plotted as % activity remaining versus kinases profiled.
Determination of Stat5a dimerization by
coimmunoprecipitation
The dimer formation of Stat5a was analyzed as described
previously (4) and in the Supplementary Methods. Cells were
serum-starved for 16 hours, followed by pretreatment with IST5-
002 or the control compound (Ctrl) for 2 hours at indicated
concentrations, and stimulated with hPrl (10 nmol/L) in serum-
free medium for 30 minutes. Whole-cell lysates were immuno-
precipitated with anti-Myc mAb (2 mg/sample; Santa Cruz Bio-
technology) and immunoblotted with anti-Flag mAb (1:1,000;
Genomics), anti-Myc mAb (1:1,000; Santa Cruz Biotechnology),
and anti-actin pAb (1:4,000; Sigma-Aldrich).
Generation of adenoviral vectors for gene delivery of Stat5 and
PrlR
pcDNA-CMV-WT-STAT5A and pcDNA-CMV-constitutively
active STAT5A (CAStat5a; Stat5aS710F; ref. 38) were cloned to
adenoviral vector using BD Adeno-X Expression System 2 (BD
Biosciences Clontech). pcDNA-CMV-WT-STAT5A and pcDNA-
CMV-constitutively active STAT5A (CAStat5a; Stat5aS710F; ref. 5)
were cloned to adenoviral vector using BD Adeno-X Expression
System 2 (BD Biosciences Clontech) according to the manufac-
turer's protocol. The purified recombinant adenovirus was line-
arized by PacI digestion and transfected to QBI-293A cells (Qbio-
gene) to produce infectious recombinant adenoviruses. The
resulting AdWTStat5a, AdCAStat5a, and AdPrlR primary viral
stocks were expanded in large-scale cultures, purified by double
cesiumchloride gradient centrifugation, and titratedby a standard
plaque assaymethod inQBI-293A cells, as per themanufacturer's
instructions.
Immunofluoresence cytochemistry of Stat5a/b and Stat3
PC-3 cells were infectedwithAdWTStat5a andAdPrlR atMOI 4.
Serum-starved (10 hours) cells were pretreated with IST5-002 or
control compound (2 hours) and stimulated with 10 nmol/L Prl
(30 minutes). For analysis of IST5-002 efficacy in inhibition of
Stat3 nuclear translocation, DU145 cells were serum-starved,
pretreated with IST5-002, AZD1480 or vehicle at indicated con-
centrations for 2 hours, before cells were stimulated with IL6
(ProSpec-Tany Technogene) at 5 nmol/L (30minutes). Fixed cells
were incubated with rabbit anti-Stat5 pAb (1:200; Santa Cruz
Biotechnology) or anti-pYStat3 pAb (1:100; Cell Signaling Tech-
nology), followed by goat anti-rabbit fluorescein IgG (1:200;
Vector Laboratories), as described previously (23).
Electrophoretic mobility shift assay
Electrophoretic mobility shift assays (EMSA) were conducted
as we have described previously (23).
Cell viability and DNA fragmentation assay
Cell viabilitywas determined by theCellTiter 96AqueousAssay
Kit (Promega). The number of living cells was also determined by
counting the attached versus nonattached cells using a hemacy-
tometer and Trypan blue exclusion. DNA fragmentation was
analyzed by photometric enzyme immunoassay according to the
manufacturer's instructions (Cell Death Detection ELISAPLUS;
Roche).
Caspase-3 activation assay
CWR22Rv1 cells were treated with IST5-002 (12.5 mmol/L) or
vehicle for indicated periods of time. Caspase-3 was captured by
anti-caspase-3 mAb, followed by caspase-3–mediated enzymatic
cleavage of 7-amino-4-trifluoromethyl-coumarin (AFC) substrate
measured at 505 nm. In Stat5a/b rescue experiments, CAStat5a
was expressed using an adenoviral vector (MOI¼ 2) 6 hours prior
to treatment of cells with IST5-002 (12.5 mmol/L) or vehicle for
72 hours.
Cell-cycle analysis
Cells were treatedwith IST5-002, vehicle, or control compound
for 24, 48, and 72 hours, fixed and stainedwith propidium iodide
(PI) and RNase A (Sigma-Aldrich). PI fluorescence intensity was
analyzed by a flow cytometer using FL-2 channel.
Colony formation assay
CML-blast crisis lines andCMLCD34þprimary cellswere plated
in the presence of DMSO, 5 mmol/L IST-002, or 5 mmol/L control
compound. After 3 hours of incubation, 1 103(K562), 2.5 103
(BV173 and KCL22), or 3  104 (CML) cells were plated in
duplicate in methylcellulose and the number of colonies was
assessed 5 to 10 days after plating.
RNA expression profiling
RNA from vehicle, IST5-002, scramble shRNA, and Stat5a/
b-shRNA was profiled in triplicate using the Affymetrix
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GeneChip Human Gene 1.0 ST microarray platform. Differ-
ential gene expression comparisons were performed for IST5-
002 versus vehicle, and Stat5a/b-shRNA versus scramble-
shRNA using a t test with false discovery rate correction.
Protocols for RNA preparation, hybridization, scanning, and
statistical analysis are described in detail in the Supplementary
Methods. The accession number for the sDNA array data are
GSE61312.
Figure 3.
IST5-002 inhibits expression of Stat5 target genes. A, IST5-002 downregulates the expression of Stat5 target genes cyclin D1 and Bcl-xL in prostate cancer cells.
Exponentially growing CWR22Rv1 and LNCaP cells were treated with IST5-002 or Ctrl and whole-cell lysates were immunoblotted with anti-cyclinD1 mAb
or anti-Bcl-xL pAb. B, expression profiling of genes regulated by both genetic knockdown of Stat5 and IST5-002 in CML cells. Stat5 was suppressed in K562 cells by
lentiviral expression of Stat5 shRNA versus scramble control for 6 days or by treatment of the cells with IST5-002 (5 mmol/L) for 48 hours. Venn diagrams
of Stat5–shRNA and/or IST5-002–regulated genes in K562 cells meeting criteria for significant up/downregulation (FDR-adjusted P < 0.05, >2-fold change; left).
Inhibition of Stat5 protein expression and phosphorylation demonstrated by immunoblotting of whole-cell lysates with anti-pYStat5 mAb and anti-Stat5
mAb versus anti-actin pAb as loading control (right). C, the heatmap represents patterns of differential expression for 102 genes (listed in Supplementary Table S2)
significantly regulated by both Stat5 knockdown and IST5-002. Red, higher expression; blue, lower expression.
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Figure 4.
IST5-002 decreases viability of human prostate cancer cells in vitro. A, CWR22Rv1, LNCaP, and DU145 cells were treated with IST5-002, Ctrl, or vehicle, and
the fraction of living cells was determined by MTS (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl-tetrazolium bromide) metabolic activity assay. B, CWR22Rv1
cells were treated with 25 mmol/L IST5-002, Ctrl, or vehicle (24 hours) followed by Trypan blue exclusion and dead cells were manually counted. C, in
parallel wells, nucleosomal DNA fragmentation, indicating cell death due to apoptosis, was demonstrated by nucleosomal ELISA at 405 nm. D, IST5-002 induces
an increase in caspase-3 activation in CWR22Rv1 cells (72 hours; P < 0.001), which was counteracted by expression of constitutively active (CA) Stat5a/b.
CWR22Rv1 cells were infected with adenovirus expressing CAStat5a (AdCAStat5a; MOI ¼ 2) 12 hours prior to treatment of cells with IST5-002 (12 mmol/L)
or vehicle, followed by determination of caspase-3 activation by fluorometric immunosorbent enzyme assay. (Continued on the following page.)
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Human prostate cancer xenograft tumor growth studies
Castrated male athymic nude mice were purchased from Taco-
nic and cared for according to the institutional guidelines. Mice
were implanted with sustained-release DHT pellets (60-day
release, 1 pellet/mouse; Innovative Research of America) 3 days
before prostate cancer cell inoculation. Briefly, 1.5  107
CWR22Rv1 cells were mixed with 0.2 mL of Matrigel (BD Bios-
ciences), and inoculated subcutaneously (s.c.) into flanks of nude
mice (one tumor/mouse) as described previously (2–4). After 1
week, tumor sizes were measured, and mice were randomly
distributed into five groups (10 mice/group). Mice were treated
daily for 10 days by intraperitoneal (i.p.) injections with 0.2 mL
of IST5-002 dissolved in 0.3% hydroxypropyl cellulose (HPC;
Sigma-Aldrich) at 25, 50, or 100 mg/kg body weight, or with
0.2 mL 0.3% HPC solution, or no treatment, and tumor sizes
were measured three times per week. Tumor volumes were
calculated using the following formula: 3.14  length  width
 depth/6. When the tumors reached 15 to 20 mm in diameter
in the control groups, mice were sacrificed and tumor tissues
were harvested. Percentage changes in tumor volume of each
group are presented.
Ex vivo organ culture testing of Stat5-inhibitor efficacy in
clinical prostate cancers
Prostate cancer specimens were obtained from patients with
localized or locally advanced prostate cancer undergoing radical
prostatectomy and bilateral iliac lymphadenectomy (Table 1).
The Thomas Jefferson University Institutional Review Board
approved this work to be in compliance with federal regulations
governing research ondeidentified specimens [45CFR46.102(f)].
A zero-sample prior to organ culture of each individual prostate
cancer was formalin-fixed for the analysis of nuclear Stat5a/b
status. Prostate organ cultures were performed as described earlier
(4, 7, 34, 39) and in the Supplementary Methods.
Stat5a/b immunohistochemistry and TUNEL assay of paraffin-
embedded tissue sections
Immunohistochemistry (IHC) staining of Stat5a/b and termi-
nal deoxynucleotidyl transferase–mediated dUTP nick end label-
ing (TUNEL) assay were performed as described previously (1, 3–
5, 7, 8, 21). Viable, active nuclear Stat5a/b-positive, Stat3-positive,
or apoptotic (fragmented DNA) cells versus total number of cells
(viable and dead) were counted for 3 views/tumor and 1 view
covering each organ culture explant (20–25 explants per treat-
ment group per patient) and expressed as percentages, as dem-
onstrated previously (4). The average cell number per explant is
determined of a sample of each patient prior to culture. All
percentages within each treatment group (tumor or organ culture
explant) were averaged.
Statistical analyses
Mixed-effects linear regression was used to model log 10–
transformed tumor volumes. A quadratic curve in time was
modeled separately for each treatment group. Random terms
were included for the intercept, slope, and quadratic effect,
allowing for each animal's curve to differ from the mean curve
in its group. Differences in the groups with respect to the geo-
metric mean tumor volume at days 1, 3, 6, 8, and 10 were tested,
and at day 10, pairwise comparisons were performed to identify
which groups differed from each other. P values were adjusted
using Bonferroni method. P < 0.05 was considered significant.
For tumor cell viability and nuclear Stat5 or Stat3 levels,
analysis of variance implemented in SAS ProcMIXED was used
to test for differences in responses across groups. Pairwise com-
parisons were performed to compare each inhibitor dose to the
control groups and P values for pairwise comparisons were
adjusted using the Bonferroni method.
For cancer cell viability and nuclear Stat5 content in organ
explant cultures, mixed-effects linear regression was used for
statistical analysis of responders, followed by pairwise compar-
isons adjusted using the Bonferroni method. For nonresponders,
the Kruskal–Wallis test was used because of the small number of
measurements for each group.
Results
Virtual screen identifies a small molecule inhibitor of Stat5a/b
phosphorylation and dimerization
To identify a family of Stat5a/b inhibitor compounds, we used
in silico structure-based screening andmedicinal chemistry. Dock-
ing of the most promising compound, inhibitor of Stat5-002
(IST5-002), to the binding site of the Stat5b SH2 domain is
depicted (Fig. 1A–C). Chemical structures of IST5-002 (MW
437Da), a randomly selected control compound (Ctrl) of similar
molecular weight (343 Da; Fig. 1D) and other IST5-family mem-
bers (Supplementary Fig. S1) are shown.
To determine whether IST5-002 blocks Stat5a/b transcrip-
tional activity, PC-3 cells were cotransfected with PrlR, Stat5a or
Stat5b, and a Stat5a/b-luciferase reporter (b-casein-luciferase).
Cells were treated with IST5-002 or Ctrl for 2 hours prior to
and during Stat5a/b activation by stimulation with human
prolactin (hPrl, 10 nmol/L; 16 hours). IST5-002 robustly in-
hibited transcriptional activity of Stat5a (IC50 ¼ 1.5 mmol/L)
and Stat5b (IC50 ¼ 3.5 mmol/L) in a dose-dependent manner,
compared with Ctrl (Fig. 1E). Design and synthesis of IST5-002
analogs and structure–activity relationship (SAR) studies (Sup-
plementary Table S1) identified a family of IST5-002 inhibitors
(Supplementary Fig. S1) that displayed efficacies comparable
with IST5-002.
To analyze whether IST5-002 suppresses formation of tran-
scriptionally active phosphorylated dimers, Bcr-Abl–positive
K562 cells were treated with increasing concentrations of IST5-
002 (3 hours), using pimozide (15) and Ctrl as positive and nega-
tive controls, respectively. Remarkably, IST5-002 blocked Bcr-Abl–
induced Stat5a/b phosphorylation at 5 mmol/L (Fig. 1F). At the
same time, pimozide, a previously reported Stat5a/b inhibitor
(Continued.) E, IST5-002 increases the fraction of dead prostate cancer cells in cell-cycle analysis. LNCaP and CWR22Rv1 cells were treated with
IST5-002 or Ctrl for 72 hours at indicated concentrations followed by FACS analysis. F, CWR22Rv1 cells were treated with IST5-002 at indicated
concentrations or transduced with lentiviral shStat5a/b (Stat5a/b–shRNA) or control shRNA (scramble-shRNA) for 72 hours and alive cells were
counted manually after Trypan blue exclusion. G, to test the effect of IST5-002 on prostate cancer cell viability after genetic knockdown of Stat5a/b,
CWR22Rv1 cells were first transduced with lentiviral Stat5a/b shRNA (Stat5a/b-shRNA) or control shRNA (scramble-shRNA). After 24 hours, the
cells were treated with IST5-002 (12.5 mmol/L) or control compound (Ctrl) for 48 hours and alive cells were counted manually after Trypan
blue exclusion.
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Figure 5.
IST5-002 inhibits prostate cancer xenograft tumor growth in vivo in nude mice. A, CWR22Rv1 prostate cancer cells were inoculated subcutaneously
into the flanks of castrated athymic nude mice supplied with sustained-release 5a-DHT pellets (n ¼ 10/group, 1 tumor/mouse, 1.5  107 CWR22Rv1
cells per site, 1 DHT pellet/mouse). Mice were treated with IST5-002 (25, 50, and 100 mg/kg) or vehicle (HPC) as control i.p. daily, with a group with
no treatment as an additional control. Tumor sizes were measured every 3 days, and tumor volumes were calculated using the formula V ¼ (p/6)  d1
(d2)
2, with d1 and d2 being two perpendicular tumor diameters. (Continued on the following page.)
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(15), required 20 to 40 mmol/L to fully block Stat5a/b phosphor-
ylation under these same conditions. However, pimozide is likely
to induce a number of off-target effects related to the high con-
centrations needed for Stat5a/b inhibition. IST5-002 did not affect
Bcr-Abl tyrosine phosphorylation levels in K562 cells (Fig. 1F).
Next, serum-starved CWR22Rv1, HC-11, and T47D cells were
treated with IST5-002 (2 hours), followed by stimulation with
hPrl (30 minutes). For CWR22Rv1 (Fig. 1G) and HC-11 (Supple-
mentary Fig. S2A) cells, Stat5a/b were immunoprecipitated and
immunoblotted with anti-pYStat5a/b antibody (Fig. 1G), while a
cell-based immunoassay was used to monitor Stat5a/b
phosphorylation in T47D cells (Supplementary Fig. S2B). IST5-
002 blocked phosphorylation of Stat5a/b (CWR22Rv1, IC50 ¼ 22
mmol/L; HC-11, IC50 ¼ 12 mmol/L; T47D, IC50 ¼ 24.8 mmol/L),
while total Stat5a/b levels remained unaffected. Phosphorylation
of Jak2 was unaffected by IST5-002, indicating that IST5-002
does not inhibit Jak2 (Fig. 1G). Moreover, kinase activity profiling
assay indicated no specific inhibition of other kinases in a panel
of 50 kinases by IST5-002 (Supplementary Fig. S3), including
activity of PAK1/2 (Supplementary Fig. S4; ref. 40). To test
whether IST5-002 disrupts dimerization of Stat5a/b, we
generated and cotransfected FLAG- and MYC-tagged Stat5a
into PC-3 cells along with PrlR. Serum-starved cells were
treated with IST5-002 or Ctrl before stimulation with hPrl
(10 nmol/L; 30 minutes). Lysates were immunoprecipitated
with anti-Myc antibodies and immunoblotted with anti-Flag
or anti-Myc antibodies. As expected, hPrl stimulation induced
Stat5a dimerization, which was inhibited by IST5-002 (IC50 ¼
11 mmol/L; Fig. 1H). We conclude that IST5-002 effectively
blocks molecular events associated with Stat5a/b activation,
including phosphorylation, dimerization, and transcriptional
activity.
IST5-002 suppresses downstream signaling events and target
gene expression induced by Stat5a/b in prostate cancer and
CML cells
We next investigated whether IST5-002 disrupts downstream
signaling events induced by Stat5a/b activation. To assess if
nuclear translocation of Stat5a/b is affected, we expressed Stat5a
and PrlR in PC-3 cells and treated serum-starved cells with IST5-
002 (2 hours), prior to stimulation with hPrl (10 nmol/L; 30
minutes). In the absence of hPrl, Stat5a was predominantly
localized in the cytoplasm, as demonstrated by immunocyto-
chemistry (Fig. 2A). Addition of hPrl robustly induced Stat5a
nuclear translocation, which was abrogated by IST5-002 at 15
mmol/L (Fig. 2A).
To determine whether IST5-002 inhibits DNA binding of
activated Stat5a/b, we used EMSA using the Stat5a/b response
element of the b-casein gene promoter as a probe (Fig. 2B). COS-7
cells transfected with PrlR and Stat5a were serum-starved and
pretreated with IST5-002 (2 hours), followed by hPrl stimulation
(10 nmol/L; 30minutes). As predicted, IST5-002 reduced binding
of Stat5a/b to its DNA target sequence by approximately 50% at
25 mmol/L, compared with Ctrl-treated cells (Fig. 2B).
To evaluate specificity of IST5-002 for Stat5a/b, we tested the
ability of IST5-002 to inhibit nuclear translocation and tran-
scriptional activity of IL6-induced Stat3. Serum-starved DU145
cells were pretreated with IST5-002 or a positive control com-
pound, Jak2 inhibitor AZD1480 (4, 41), before stimulation
with IL6 (5 nmol/L). Although AZD1480 effectively suppressed
Stat3 nuclear translocation, IST5-002 had no demonstrable
effect, even at a higher concentration (50 mmol/L; Fig. 2C).
We reconstituted the IL6-receptor–Stat3 signaling pathway in
LNCaP cells and introduced a Stat3-luciferase reporter. Serum-
starved cells were pretreated with IST5-002 (1 hour) and
stimulated with IL6 (50 ng/mL; 16 hours). IST5-002 failed to
block transcriptional activity of Stat3 (Fig. 2D) at a concentra-
tion that was highly effective at inhibiting Stat5a/b-driven
transcription (Fig. 1E).
To assess the ability of IST5-002 to regulate the expression of
Stat5a/b target genes in prostate cancer cells, CWR22Rv1 and
LNCaP cells were treated with increasing concentrations of IST5-
002 or Ctrl (48 hours; Fig. 3A), or a single dose of IST5-002 (25
mmol/L) or Ctrl for the indicated times (Supplementary Fig. S5A).
Immunoblotting of prostate cancer cell lysates showed that IST5-
002 reduced expression of both Bcl-xL and cyclin D1 (Fig. 3A and
Supplementary Fig. S5A), both previously demonstrated as
Stat5a/b target genes in prostate cancer cells (2). We further
assessed the gene expression profiles induced by genetic
(Stat5a/b shRNA) or pharmacologic (IST5-002) knockdown of
Stat5a/b in CML cells, as verified by immunoblotting (Fig. 3B).
Genes (Supplementary Fig. S5B) regulated by both Stat5a/b-
silencing and IST5-002 in CML cells are presented as Venn dia-
grams (Fig. 3B). The statistically significant (P < 0.01) similarity
between the gene expression changes induced by IST5-002 treat-
ment and Stat5a/b knockdown in K562 cells indicate that these
transcriptional changes are primarily due to loss of Stat5a/b
activity and not to off-target effects (Fig. 3C and Supplementary
Tables S2–S5). Among known Stat5a/b target genes regulated by
IST5-002 were cyclin D2 (2.3-fold), Pim1 (1.7-fold), Pim2
(1.7-fold), Myc (1.7-fold), SOCS3 (1.3-fold), CISH (2.3-
fold), and TRIB2 (1.4-fold; Supplementary Table S5). Gene
ontology enrichment analysis revealed genes involved in meta-
bolic processes, proliferation, processing of extracellular stimuli
and remodeling actin cytoskeleton (Supplementary Fig. S5C).
IST5-002 suppresses Stat5a/b-mediated growth of prostate
cancer through induction of apoptosis in experimental models
of prostate cancer in vitro, in vivo, and ex vivo
To investigate the effect of IST5-002 in prostate cancer cell
growth, we treated three human prostate cancer cell lines
with IST5-002 or Ctrl (72 hours). In all three cell lines, IST5-
002 decreased viable cells by 50% to 80% at 12.5 mmol/L (P <
0.001; Fig. 4A). Treatment of CWR22Rv1 cells with 25 mmol/L
IST5-002 (24 hours) resulted in a 5-fold increase in dead cells,
as detected by Trypan blue exclusion (Fig. 4B). In parallel wells,
IST5-002 increased nucleosomal DNA fragmentation by
230%, suggesting that the mode of cell death was apoptotic
(Continued.) Columns represent percentage change in tumor volume and growth of individual tumors. Tumor growth was significantly (P < 0.001)
suppressed in all IST5-002 treatment groups compared with the control groups. B, IST5-002 induces apoptotic cell death in CWR22Rv1 prostate
cancer xenograft tumors. Hematoxylin and eosin staining of the sections demonstrates loss of viable tumor cells and accumulation of dead cells (arrows)
in IST5-002–treated CWR22Rv1 xenograft tumors versus controls. C, immunostaining of nuclear active Stat5a/b or (d) Stat3 of paraffin-embedded
sections of the prostate xenograft tumors.
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(P < 0.001; Fig. 4C). IST5-002 (12.5 mmol/L) induced a 3-fold
increase in caspase-3 activation (P < 0.001; Fig. 4D). Important-
ly, overexpression of constitutively active Stat5a/b (3) by ade-
noviral vector (CAStat5a) 12 hours prior to treatment with
12.5 mmol/L IST5-002 prevented caspase-3 activation by IST5-
002 (Fig. 4D). Cell-cycle analysis of IST5-002- or Ctrl-treated
(72 hours) LNCaP and CWR22Rv1 cells revealed that IST5-002
increased the fraction of dead cells (sub-G1) and decreased the
fraction of living cells (G2–M; Fig. 4E). Treatment of CWR22Rv1
cells for 72 hours with IST5-002 shows comparable efficacy to
genetic knockdown of Stat5a/b by lentiviral transduction of
Stat5a/b shRNA (Fig. 4F). Moreover, to test the effect of IST5-
002 on the viability of prostate cancer cells after Stat5a/b had
been genetically deleted, CWR22Rv1 cells were first transduced
by lentiviral Stat5a/b shRNA versus control shRNA for 24 hours
followed by treatment with IST5-002 for 48 hours. Although
IST5-002 (12.5 mmol/L) induced 40% decrease in the number
of viable prostate cancer cells expressing control shRNA, IST5-
002 did not further affect viability of CWR22Rv1 cells depleted
of Stat5a/b (shStat5a/b; Fig. 4g). IST5-002 effects were prostate
cancer–specific, as viability of malignant or immortalized cell
lines originating from other tissues, including lung (A549),
pancreas (CAPAN), breast (T47D), fibrosarcoma (HT1080),
liver (HepG2), or monkey fibroblasts (COS-7), was not affected
(Supplementary Fig. S6A). When tested side-by-side, IST5-002
suppressed viability of prostate cancer (CWR22Rv1) and CML
(K562) cells that both have high Stat5a/b activation, while IST5-
002 did not affect viability of cell lines with low or no Stat5a/b
activation (RC170N—normal prostate epithelial cell line;
HT1080—fibrosarcoma cells; Supplementary Fig. S6B).
To determine whether IST5-002 efficacy extended to an in vivo
model of prostate cancer, we inoculated CWR22Rv1 cells subcu-
taneously into the flanks of nude mice (Fig. 5A). Once prostate
cancer xenograft tumors were established, mice were treated daily
by i.p. injection of IST5-002 (25, 50, or 100 mg/kg) or vehicle
(HPC). Tumor growth was significantly (P < 0.001) suppressed in
all IST5-002 treatment groups compared with the control groups
(Fig. 5A and Supplementary Fig. S7). IST5-002 induced massive
loss of viable tumor cells and accumulation of dead rounded cells
(P < 0.001; IST5-002 groups versus vehicle; Fig. 5B). IST5-002
induced cell death through apoptosis, as shownby the presence of
fragmented DNA in tumor sections (Supplementary Fig. S8A).
IST5-002 decreased nuclear Stat5a/b content by 60%, 78%, and
90% in groups treated with 25, 50, and 100 mg/kg, respectively,
compared with vehicle (HPC; P < 0.0001; Fig. 5C). Intratumor
levels of nuclear Stat3 were not altered at any of the doses tested
(Fig. 5D). Together, these results indicate that IST5-002 sup-
presses prostate cancer growth in vitro and in vivo, without general
toxicity in normal prostate epithelial cells or solid tumor cells
originating from other organs.
To evaluate efficacy of IST5-002 in clinical prostate cancer, we
exploited an ex vivo organ explant culture system of patient-
derived prostate cancers from radical prostatectomies that we
have previously established and characterized (4, 7, 34, 39). All
tested clinical prostate cancers (n ¼ 11) were of Gleason score 7
(Table 1), andwere cultured for 7 days in the presence of IST5-002
or Ctrl at the indicated concentrations. Eight out of 11 patient-
derived prostate cancers responded to IST5-002 by extensive loss
of viable epithelium, starting at 25 mmol/L (P ¼ 0.004; Fig. 6A).
IST5-002 induced apoptotic death of explant epithelial cells in
cancer acini, compared with explants cultured with Ctrl (P ¼
0.002). Apoptosis was evidenced by accumulation of dead cells in
acinar lumens (Supplementary Fig. S8B). Three out of 11 prostate
cancers did not show reduced epithelial cell viability in response
to IST5-002 (Fig. 6A, right). Nuclear Stat5a/b contents showed a
trend of downregulation by IST5-002 in the eight responsive
prostate cancers, but were lower and remained largely unaffected
in the nonresponsive prostate cancers (Fig. 6B). To determine
whether Stat5a/b activation status could predict IST5-002 respon-
siveness in organ explant culture, we analyzed nuclear Stat5a/b
levels in samples prior to culture. All nonresponsive prostate
cancers had low or nonexistent nuclear Stat5a/b expression, while
nuclear Stat5a/b immunostaining was moderate or strong in all
responsive prostate cancers (Table 1). These results indicate that
IST5-002 induces death of primary prostate cancer cells with high
nuclear Stat5a/b expression.
IST5-002 inhibits Stat5a/b phosphorylation and induces
apoptosis of imatinib-sensitive and -resistant CML cells
To determine IST5-002 efficacy in disrupting Stat5a/b phos-
phorylation in Bcr-Abl-driven leukemias, parental and imatinib-
resistant CML cell lines (K562, KCL22, and BV173) were cultured
for 24 to 72 hours with increasing concentrations of IST5-002.
IST5-002 potently inhibited Stat5a/b phosphorylation in both
imatinib-sensitive and -resistant CML cells (IC50¼ 2.5–7 mmol/L;
Fig. 7A and B). Because Stat5a/b signaling is critical for Bcr-Abl–
driven growth of CML cells, we investigated whether IST5-002
affects viability of these cells. The number of living cells was
assessed by Trypan blue exclusion after treatment with IST5-002
(5 mmol/L) for increasing periods of time (Fig. 8A), or by colony
formation assay (Supplementary Fig. S9). In both assays, treat-
ment with IST5-002 blocked the growth of imatinib-sensitive and
-resistant CML cells. Cell-cycle analysis of IST5-002–treated cells
at 48 hours showed an increase in apoptosis and a decrease in the
fraction ofG2–Mor S-phase cells (Fig. 8B). Furthermore, IST5-002
decreased viability of acute lymphocytic leukemia (ALL) cell line
(SUP-B15) that is driven by Bcr-Abl and has high Stat5a/b
phosphorylation (Fig. 8C). At the same time, IST5-002 had only
marginal or no effect on the viability of EBV-immortalized B cells
that express no active Stat5a/b (Fig. 8C). To evaluate IST5-002
efficacy in primary CML samples, cells obtained from three CML-
chronic phase patients (n ¼ 3) were plated in methylcellulose in
the presence of IST5-002 and colonies were counted after 7 days.
In all three samples, IST5-002 suppressed cell growth, as indicated
by the dramatic decrease in the number of viable colonies (Fig.
8D). In conclusion, IST5-002 potently inhibits Stat5a/b phos-
phorylation and growth of imatinib-sensitive and -resistant CML
cells.
Discussion
Although a critical role of Stat5a/b in pathogenesis of prostate
cancer and myeloproliferative disorders has been established
(1–22, 24), only a few pharmacologic Stat5a/b inhibitors are
currently available for clinical development (15, 42–44). In this
work, we identified a potent lead compound Stat5a/b inhibitor,
IST5-002, with high efficacy in abrogating Stat5a/b signaling in
prostate cancer and CML. IST5-002 potently inhibited molecular
events associatedwith Stat5a/b activation, reduced the expression
of Stat5a/b-regulated genes and induced extensive apoptotic
cell death in multiple models of prostate cancer and CML in vitro,
in vivo in animal models and in patient samples.
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Transcription factors are typically considered suboptimal phar-
macologic targets because their function relies on protein–protein
and protein–DNA interactions that are not easily disrupted by
small molecules. However, our strategy was to target the SH2
domain–phosphotyrosine interaction of cytoplasmic Stat5 as a
signaling molecule, prior to phosphorylation, dimerization, and
nuclear translocation. Although the structure of a fragment of
unphosphorylated Stat5a-SH2 domain has been determined
(36), this structure lacks the phosphotyrosyl bridge and, thus, is
not useful for screening molecules to target Stat5a/b SH2
Figure 6.
IST5-002 induces death of epithelial cells in
patient-derived prostate cancers ex vivo in
organ explant cultures. A, to test
responsiveness of primary prostate cancers
to IST5-002, 11 localized prostate cancers
(Table 1) were cultured for 7 days ex vivo as
explant organ cultures in basal medium in
the presence of IST5-002 at indicated
concentrations or Ctrl. Eight prostate
cancers showed loss of viable acinar
epithelium in response to IST5-002
(responders, left), while in three prostate
cancers, epithelial viability remained intact
after IST5-002 treatment (nonresponders,
right). Representative histology of an
individual prostate cancer that responded
to IST5-002 with extensive loss of acinar
epithelium (B). Immunodetection shows
intense positive immunostaining for nuclear
Stat5 in explants cultured in the presence of
Ctrl, while IST5-002 reduced levels of
nuclear Stat5 expression. Representative
immunostaining of nuclear Stat5 in a
prostate cancer that responded to IST5-002
is presented.
Small Molecule Inhibitor of Stat5a/b in Prostate Cancer and Leukemia
www.aacrjournals.org Mol Cancer Ther; 14(8) August 2015 1789
domain–pY interactions. We constructed a homology model of
Stat5a/b SH2 domain based on the crystal structures of (2 hours)
phosphorylated Stats (30, 37). The lead compound Stat5 inhib-
itor, IST5-002, showed specificity for Stat5 over Stat3. Thismay be
due to several reasons. First, the following Stat5a/b residues
were selected as binding sites for in silico screening: 600K,
Figure 7.
IST5-002 inhibits Stat5 phosphorylation in imatinib-sensitive and -resistant CML cells. A, Western blotting (left) and densitometry (right) showing the levels
of phosphorylated Stat5a/b in IST5-002–treated (12 hours) parental (sensitive) and imatinib-resistant KCL22, K562, and BV173 cells. Grb2 levels were
monitored as loading control. B, Western blotting of phosphorylated Stat5a/b levels in imatinib-sensitive or -resistant (T315I) BV173 cells treated with IST5-002
or imatinib at the indicated concentrations for 6, 12, or 24 hours.
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604H, 618-RFSDSEIGG-626, 628T, 638-RMFWNLMPF-646, 707-
VVPE-710. A comparison of these sites to the corresponding
sequences in Stat3 reveals 15 differences, five ofwhich are changes
from hydrophobic (Stat5a/b) to charged (Stat3) amino acids.
Moreover, the Stat3 sequence contains an inserted serine residue
corresponding to a position between residues 622S and 623E in
Stat5a/b. Although thedata presented in thepresent studyprovide
evidence for IST5-002 inhibition of Stat5a/b phosphorylation
and dimerization in multiple model systems, future work will
need to evaluate whether IST5-002 directly binds to the SH2
domain of Stat5a/b.
A number of nucleoside analogs structurally similar to IST5-
002 (N6-benzyladenosine-5-monophosphate; ref. 45), such as 2-
chlorodeoxyadenosine, fludarabine, pentostatin, and cladribine,
are currently in use as anticancer drugs (46, 47). Fludarabine was
recently shown to inhibit Stat1 phosphorylation and activation
Figure 8.
IST5-002 induces extensive apoptotic death of imatinib-sensitive and -resistant CML cells. A, cell counts (Trypan blue exclusion) of IST5-002–treated (5 mmol/L)
imatinib-sensitive and -resistant CML blast crisis cell lines. B, cell-cycle distribution of control (medium, DMSO, or Ctrl) or IST5-002-treated (5 mmol/L)
CML-blast crisis cell lines. C, IST5-002 decreases viability of Bcr-Abl–driven lymphoid blast crisis cells (BV173) and ALL cells (SUP-B15) with high Stat5 activation,
while having marginal effect on EBV-immortalized B cells with no Stat5a/b activation (12878, 3798). Levels of STAT5 phosphorylation of Bcr-Abl–expressing
BV173 and SUP-B15 cell lines, and Bcr-Abl–negative, EBV-immortalized 12878 and 3798 B-cell lines (top left). Cell viability (MTT assay) of IST5-002–treated
(48 hours) BV173, SUP-B15, 12878, and 3798 cell lines (top right). Levels of STAT5 phosphorylation of SUP-B15 andBV173 after 12 hours of treatmentwith IST5-005 or
Ctrl at the indicated concentrations (bottom). D, colony formation of IST5-002–treated primary CML-chronic phase cells from patients. Colonies were
counted 9 days after plating and the results are expressed as percentage colony formation inhibition of treated versus untreated cells.
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but not affecting Stat5 activity (48). Analogous to fludarabine,
IST5-002 inhibited molecular events involved in Stat5a/b activa-
tion while not affecting Stat3 activation. Moreover, IST5-002
induced extensive apoptosis selectively in two cancers known to
be driven by Stat5a/b, prostate cancer, and CML, but was not
generally cytotoxic to normal epithelial cells and affected only
marginally the viability of other types of cancers not driven by
Stat5a/b and with low or no Stat5a/b activation. Although IST5-
002 is a close derivative of AMP, AMP or similar mononucleo-
tides, such as GMP and cyclic AMP, had no effect on Stat5a/b
activation and transcriptional activity when tested side-by-side
with IST5-002 (data not shown). The IC50 values of IST5-002 for
suppression of transcriptional activity, phosphorylation, dimer-
ization, nuclear translocation, and viability varied between 1.5
and 22 mmol/L. This is likely due to variability in the sensitivities
of different assays as well as differences between cell lines in their
dependence on Stat5 for survival.
Stat5a/b has been previously established as a candidate
therapeutic target protein in prostate cancer (2, 4, 9, 20, 21).
IST5-002 robustly inhibited viability of Jak2-Stat5a/b–driven
prostate cancer cells in culture and growth of xenograft tumors
in nude mice. Moreover, IST5-002 induced extensive epithelial
cell death in the majority of 11 clinical prostate cancers when
tested ex vivo in organ explant cultures. Recently, pharmacologic
targeting of Stat5a/b by a Jak2 inhibitor, AZD1480, was shown
to block growth of CRPC (4). Direct pharmacologic inhibition
of Stat5a/b is likely to target a larger fraction of clinical prostate
cancers than targeting the kinase, because Stat5a/b is a conver-
gence point for multiple kinases in prostate cancer, including
Jak2, Src, and EGF receptor family members (3, 31–35). Of
note, positive status for active Stat5a/b in 11 clinical prostate
cancers predicted responsiveness to IST5-002 in ex vivo explant
cultures, suggesting that Stat5a/b activation in prostate cancer
biopsies could potentially serve as a biomarker for therapy
selection.
IST5-002 induced extensive apoptotic death of both imati-
nib-sensitive and -resistant CML cells through potent inhibition
of Stat5a/b. Moreover, IST5-002 blocked growth of primary
CML-chronic phase cells. Current therapy for CML includes
imatinib, dasatinib, and nilotinib, which reduce Bcr-Abl kinase
activity and Stat5a/b activation (49). Our data indicated high
efficacy of IST5-002, suppressing growth of both imatinib-
sensitive and -resistant CML cells. However, a key concern in
CML therapy is the emergence of resistance to multiple kinase
inhibitors, known to develop through Bcr-Abl point mutations
(particularly T315I; ref. 49) or overexpression. Pharmacologic
inhibition of Stat5a/b directly may provide an improved
strategy for CML therapy, either after development of resistance
to current kinase inhibitors or as a part of an initial combina-
tion therapy to prevent acquired resistance.
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